Inhibition of angiogenesis for the treatment of metastatic melanoma

Current Oncology Reports

Volumn 15, Issue 5, 2013, Pages 492-499

  Mansfield, Aaron S ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Bevacizumab; Metastatic Melanoma; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ALPHA2B INTERFERON; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CILENGITIDE; DACARBAZINE; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 2; FOTEMUSTINE; INTERLEUKIN 8; INTETUMUMAB; IPILIMUMAB; LENALIDOMIDE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; TEMOZOLOMIDE; THALIDOMIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VEMURAFENIB;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CUTANEOUS MELANOMA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; METASTATIC MELANOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR IMMUNITY; UVEA MELANOMA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84884563829     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0334-4     Document Type: Article

References (82)

1. Markovic S, Erickson L, Rao R, Weenig R, Pockaj B, Bardia A, et al. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc. 2007;82(4):490-513.
2. Markovic S, Erickson L, Rao R, Weenig R, Pockaj B, Bardia A, et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007;82(3):364-80.
3. Hodi F, O'Day S, McDermott D, Weber R, Sosman J, Haanen J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med. 2010;363(8):711-23.
4. Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med. 2011;364(26):2507-16.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
6. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med. 1971;285(21):1182-6.
7. Neitzel L, Neitzel C, Magee K, Malafa M. Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol. 1999;6(1):70-4.
8. Carnochan P, Briggs J, Westbury G, Davies A. The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness. Br J Cancer. 1991;64(1):102-7.
9. Zaki K, Basu B, Corrie P. The role of angiogenesis inhibitors in the management of melanoma. Curr Top Med Chem. 2012;12(1):32-49.
10. Boone B, Blokx W, De Bacquer D, Lambert J, Ruiter D, Brochez L. The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Arch. 2008;453(3):257-65.
11. Schietroma C, Cianfarani F, Lacal P, Odorisio T, Orecchia A, Kanitakis J, et al. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer. 2003;98(4):789-97.
12. Massi D, Puig S, Franchi A, Malvehy J, Vidal-Sicart S, González-Cao M, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol. 2006;59(2):166-73.
13. Mihic-Probst D, Ikenberg K, Tinguely M, Schraml P, Behnke S, Seifert B, et al. Tumor cell plasticity and angiogenesis in human melanomas. PLoS One. 2012;7(3):e33571.
14. Mehnert J, McCarthy M, Jilaveanu L, Flaherty K, Aziz S, Camp R, et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol. 2010;41(3):375-84.
15. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19(2):577-83.
16. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 2006;16(5):405-11.
17. Mouawad R, Spano J-P, Comperat E, Capron F, Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer. 2009;45(8):1407-14.
18. Nevala W, Vachon C, Leontovich A, Scott C, Thompson M, Markovic S. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res. 2009;15(6):1931-9.
19. Gabrilovich D, Chen H, Girgis K, Cunningham H, Meny G, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096-103.
20. Ohm J, Gabrilovich D, Sempowski G, Kisseleva E, Parman K, Nadaf S, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101(12):4878-86.
21. van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst. 2004;96(19):1473-7.
22. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res. 2012;18(10):2726-32.
23. Vartanian A, Stepanova E, Grigorieva I, Solomko E, Baryshnikov A, Lichinitser M. VEGFR1 and PKCα signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner. Melanoma Res. 2011;21(2):91-8.
24. Kerbel R, Kamen B. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423-36.
25. Varker K, Biber J, Kefauver C, Jensen R, Lehman A, Young D, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007;14(8):2367-76.
26. Perez D, Suman V, Fitch T, Amatruda T, Morton R, Jilani S, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer. 2009;115(1):119-27.
27. •• Kim K, Sosman J, Fruehauf J, Linette G, Markovic S, McDermott D, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012;30(1):34-41. This report is the largest study to date on the effects of bevacizumab in combination with cytotoxic combination chemotherapy for the treatment of metastatic melanoma.
28. Minor D. Bevacizumab Advanced Melanoma (BEAM) was a positive trial. J Clin Oncol. 2012;30(16):4.
29. Hodi FS, Friedlander PA, Atikins MB, McDermott DF, Lawrence DP, Ibrahim N, Wu X, Zhou J, Giobbie-Hurder A, Murphy G, et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2011;29(15 Suppl):Abstr 8511.
30. von Moos R, Seifert B, Simcock M, Goldinger S, Gillessen S, Ochsenbein A, et al. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol. 2012;23(2):531-6.
31. • Kottschade L, Suman V, Perez D, McWilliams R, Kaur J, Amatruda T, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775. Cancer. 2013;119(3):586-92. This trial investigated the use of nab-paclitaxel in the treatment of melanoma.
32. Avril M, Aamdal S, Grob J, Hauschild A, Mohr P, Bonerandi J, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22(6):1118-25.
33. Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli M, et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res. 2010;16(23):5862-72.
34. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499-506.
35. Tarhini A, Frankel P, Margolin K, Christensen S, Ruel C, Shipe-Spotloe J, et al. Aflibercept (VEGF trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011;17(20):6574-81.
36. Singh R, Gutman M, Bucana C, Sanchez R, Llansa N, Fidler I. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 1995;92(10):4562-6.
37. Eggermont AM, Suciu S, Testori A, Santinami M, Kruit W, Marsden J, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810-8.
38. Grignol V, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, et al. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother. 2011;34(6):509-15.
39. Vihinen P, Hernberg M, Vuoristo M-S, Tyynelä K, Laukka M, Lundin J, et al. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res. 2010;20(4):318-25.
40. Vihinen P, Ramadan S, Vuoristo M-S, Hernberg M, Tyynelä-Korhonen K, Skyttä T, et al. Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. Melanoma Res. 2011;21(5):431-7.
41. Peterson A, Swiger S, Stadler W, Medved M, Karczmar G, Gajewski T. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004;10(12 Pt 1):4048-54.
42. Pharmacia Corporation. Pharmacia announces closing of SU5416 (semaxanib) clinical trials. Retrieved from http://www.prnewswire.com/news-releases/ pharmacia-announces-closing-of-su5416-semaxanib-clinical-trials-75895232.html Accessed 29 Aug 2013.
43. Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.
44. Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-109.
45. Eisen T, Ahmad T, Flaherty K, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581-6.
46. Flaherty K, Lee S, Zhao F, Schuchter L, Flaherty L, Kefford R, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013;31(3):373-9.
47. Hauschild A, Agarwala S, Trefzer U, Hogg D, Robert C, Hersey P, et al. Gille J, et al Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27(17):2823-30.
48. McDermott D, Sosman J, Gonzalez R, Hodi F, Linette G, Richards J, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008;26(13):2178-85.
49. Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, et al. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer. 2011;105(3):353-9.
50. Amaravadi R, Schuchter L, McDermott D, Kramer A, Giles L, Gramlich K, et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res. 2009;15(24):7711-8.
51. Fruehauf J, Lutzky J, McDermott D, Brown C, Meric J-B, Rosbrook B, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011;17(23):7462-9.
52. Rini B, Schiller J, Fruehauf J, Cohen E, Tarazi J, Rosbrook B, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011;17(11):3841-9.
53. Atkins M, Kunkel L, Sznol M, Rosenberg S. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6 Suppl 1:4.
54. Santimaria M, Moscatelli G, Viale G, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003;9(2):571-9.
55. Eigentler T, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res. 2011;17(24):7732-42.
56. Schwartz E. Antivascular actions of microtubule-binding drugs. Clin Cancer Res. 2009;15(8):2594-601.
57. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli M, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2(11):1843-9.
58. Grant D, Williams T, Zahaczewsky M, Dicker A. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer. 2003;104(1):121-9.
59. Baird R, Tan D, Kaye S. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol. 2010;7(10):575-82.
60. Bedikian A, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004;14(1):63-6.
61. Jones M, Wang H, Peskar B, Levin E, Itani R, Sarfeh I, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5(12):1418-23.
62. Merchan J, Jayaram D, Supko J, He X, Bubley G, Sukhatme V. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer. 2005;113(3):490-8.
63. • Bhatt R, Merchan J, Parker R, Wu H-K, Zhang L, Seery V, et al. A phase 2 pilot trial of low-dose, continuous infusion, or « metronomic» paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer. 2010;116(7):1751-6. This trial investigated the use of metronomic chemotherapy for the treatment of melanoma.
64. D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91(9):4082-5.
65. Reiriz A, Richter M, Fernandes S, Cancela A, Costa T, Di Leone L, et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res. 2004;14(6):527-31.
66. Pawlak W, Legha S. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res. 2004;14(1):57-62.
67. Vestermark L, Larsen S, Lindeløv B, Bastholt L. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol. 2008;47(8):1526-30.
68. Solti M, Berd D, Mastrangelo M, Sato T. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res. 2007;17(4):225-31.
69. Mita M, Rowinsky E, Forero L, Eckhart S, Izbicka E, Weiss G, et al. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2007;59(2):165-74.
70. Clark J, Moon J, Hutchins L, Sosman J, Kast W, Da Silva D, et al. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer. 2010;116(2):424-31.
71. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol. 2003;21(13):2551-7.
72. Hwu W-J, Krown S, Menell J, Panageas K, Merrell J, Lamb L, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003;21(17):3351-6.
73. Hwu W-J, Lis E, Menell J, Panageas K, Lamb L, Merrell J, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer. 2005;103(12):2590-7.
74. Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight R, et al. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer. 2010;116(1):146-54.
75. Tolsma S, Volpert O, Good D, Frazier W, Polverini P, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol. 1993;122(2):497-511.
76. Volpert O, Tolsma S, Pellerin S, Feige J, Chen H, Mosher D, et al. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun. 1995;217(1):326-32.
77. Markovic S, Suman V, Rao R, Ingle J, Kaur J, Erickson L, et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007;30(3):303-9.
78. Tucker G. Integrins: molecular targets in cancer therapy. Curr Oncol Rep. 2006;8(2):96-103.
79. O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, et al. A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011;105(3):346-52.
80. Kim K, Prieto V, Joseph R, Diwan A, Gallick G, Papadopoulos N, et al. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res. 2012;22(4):294-301.
81. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51.
82. Hainsworth J, Infante J, Spigel D, Peyton J, Thompson D, Lane C, et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116(17):4122-9.